发布求助
文献互助 智能选刊 最新文献

Glavvrač (Chief Medical Officer)最新文献

筛选
英文 中文
Application of interactive methods in the study of antibiotic therapy in the subject of clinical pharmacology 交互方法在临床药理学抗生素治疗研究中的应用
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-22
S. Kasymova, M. Khabirova
{"title":"Application of interactive methods in the study of antibiotic therapy in the subject of clinical pharmacology","authors":"S. Kasymova, M. Khabirova","doi":"10.33920/med-03-2208-22","DOIUrl":"https://doi.org/10.33920/med-03-2208-22","url":null,"abstract":"At present, almost all developed countries of the world have realized the need to reform their education systems so that students really become the central figure in the educational process, and so that the cognitive activity of the student is in the center of attention of teachers and researchers. The preparation of a highly qualified specialist who is in demand in the market and able to independently make decisions within the framework of professional competence is the main task of the teacher. Such training is impossible without the introduction of new forms and methods of teaching. The purpose and objectives of the work: to determine the effectiveness of the introduction of modern interactive teaching methods into the educational process during a practical lesson on the topic \"Antibiotic Therapy\" in Clinical Pharmacology.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"150 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116357471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse drug reaction detected as a result of taking a combined antiseptic medicine 联合使用抗菌药物后发现药物不良反应
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-04
A. Kuchaeva, R. F. Gaĭfullin, D.B. Timerkaeva, M. Maksimov, E. B. Mikhailova
{"title":"Adverse drug reaction detected as a result of taking a combined antiseptic medicine","authors":"A. Kuchaeva, R. F. Gaĭfullin, D.B. Timerkaeva, M. Maksimov, E. B. Mikhailova","doi":"10.33920/med-03-2208-04","DOIUrl":"https://doi.org/10.33920/med-03-2208-04","url":null,"abstract":"Antiseptic drugs (R02AA) are the most commonly used symptomatic drugs for the treatment of patients with symptoms of catarrhal pharyngitis. According to the ATC classification, 311 medicines belong to the group of antiseptic drugs. Such a variety of drugs accounts for the problem of choice and, as a result, a decrease in the effectiveness of the treatment and the manifestation of a large number of side effects. The purpose of the research: to conduct an informational and analytical study of a combined antiseptic that caused an adverse drug reaction in a patient diagnosed with pharyngitis.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132455410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary screening of potential analgesics among cyanothioacetamide derivatives 氰硫乙酰胺衍生物潜在镇痛药的初步筛选
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-08
E. Bibik, I. S. Oleĭnik, A. Saul, B. S. Krivokolysko, K. Frolov, V. Dotsenko, S. Krivokolysko
{"title":"Preliminary screening of potential analgesics among cyanothioacetamide derivatives","authors":"E. Bibik, I. S. Oleĭnik, A. Saul, B. S. Krivokolysko, K. Frolov, V. Dotsenko, S. Krivokolysko","doi":"10.33920/med-03-2208-08","DOIUrl":"https://doi.org/10.33920/med-03-2208-08","url":null,"abstract":"The aim of the research: to study the ability of cyanothioacetamide derivatives synthesized by us on the basis of the research laboratory “Khimeks”, Lugansk State University named after Volodymyr Dahl [1], which have low acute oral toxicity in experiments in vivo [2], to bind to potential biological targets.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115412036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of ceftaroline in the therapy of respiratory infections 头孢他林治疗呼吸道感染的疗效观察
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-21
A. Z. Kamliya, M. Maksimov
{"title":"Efficacy of ceftaroline in the therapy of respiratory infections","authors":"A. Z. Kamliya, M. Maksimov","doi":"10.33920/med-03-2208-21","DOIUrl":"https://doi.org/10.33920/med-03-2208-21","url":null,"abstract":"The growing resistance of infectious agents to antimicrobial drugs (AMDs) is an important issue in antimicrobial therapy. The rate of emergence of new antibiotics against the background of the development and reproduction of resistant microorganisms is in stagnation. Ceftaroline, one of the AMD representatives, has valuable properties, which, among other things, distinguish it from other antibiotics. It is especially valuable for its activity against the main causative agent of the skin and soft tissue infection S. aureus (MRSA). It also exhibits activity against penicillin-, macrolide- and fluoroquinolone-resistant pneumococci, as well as Haemophilus influenzae strains that produce beta-lactamases, and provides opportunities for the treatment of respiratory infections.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124927423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of cefepime/sulbactam in the treatment of infections caused by carbapenem-resistant bacteria 使用头孢吡肟/舒巴坦治疗碳青霉烯耐药细菌引起的感染
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-02
A. N. Koshmanova, M. Maksimov
{"title":"Use of cefepime/sulbactam in the treatment of infections caused by carbapenem-resistant bacteria","authors":"A. N. Koshmanova, M. Maksimov","doi":"10.33920/med-03-2208-02","DOIUrl":"https://doi.org/10.33920/med-03-2208-02","url":null,"abstract":"Cefepime/sulbactam is a combined antibiotic with a wide spectrum of antimicrobial activity, including cefepime, the fourth-generation cephalosporin, and sulbactam, the beta-lactamase inhibitor, in a 1:1 ratio. Cefepime/sulbactam has a bactericidal effect: it causes a disorder in cell wall synthesis due to blockade of transpeptidase and a disorder in the formation of cross-links in peptidoglycan [1]. Today, the problem of antibiotic resistance is growing rapidly. In the WHO list, a critically high level of priority for the development of new antibiotics is occupied by infections caused by ESBL-producing gram-negative bacteria that are resistant to cephalosporins, as well as carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa [2]. Infections caused by multiresistant bacteria are characterized by a longer course, require prolonged hospitalization, are very difficult to treat with modern antibacterial drugs, and increase the risk of death [3]. In this regard, a deeper study of the action of individual antibacterial drugs and their combination with β-lactamase inhibitors in the treatment of diseases caused by multiresistant microorganisms is crucial.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121938261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of autoimmune mechanisms of neuroleptics action 抗精神病药作用的自身免疫机制研究
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-16
M. Baturina, E. Beyer
{"title":"Study of autoimmune mechanisms of neuroleptics action","authors":"M. Baturina, E. Beyer","doi":"10.33920/med-03-2208-16","DOIUrl":"https://doi.org/10.33920/med-03-2208-16","url":null,"abstract":"The authors set a goal to evaluate the severity of haloperidol catalepsy depending on the level of autoantibodies to dopamine receptors and dopamine in laboratory rats that were subjected to long-term administration of neuroleptics.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128121785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approaches to studying the internal picture of treatment in patients with paranoid schizophrenia 偏执型精神分裂症患者治疗内部图景的研究方法
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-17
O. V. Bashmakova, D. G. Semenikhin
{"title":"Approaches to studying the internal picture of treatment in patients with paranoid schizophrenia","authors":"O. V. Bashmakova, D. G. Semenikhin","doi":"10.33920/med-03-2208-17","DOIUrl":"https://doi.org/10.33920/med-03-2208-17","url":null,"abstract":"The concept of the internal picture of the disease is widely used in domestic medical, as well as medical and psychological practice; its practical use increases the effectiveness of therapeutic and rehabilitation processes. The development of the concept of the internal picture of the disease is the formation of ideas about the internal picture of treatment and the internal picture of pharmacotherapy. The internal picture of treatment is defined as the patient's subjective perception of the treatment process from going to the doctor to changing the lifestyle in the dynamics of the therapeutic process. In the internal picture of treatment, sensory and intellectual levels are distinguished. The study of the internal picture of the disease in schizophrenia and the dissociation of mental functions with the separation of the associative process and emotional, sensory experience, and the presence of productive symptoms contribute to the formation of an inadequate attitude towards the disease, which enhances the patient's disadaptation.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127247708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacoeconomic features of increased costs of direct-acting and oral anticoagulants in a multidisciplinary hospital in 2019–2021 某多学科医院2019-2021年直接作用抗凝剂和口服抗凝剂成本增加的药物经济学特征
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-20
E. R. Kadyseva, L. Kulagina
{"title":"Pharmacoeconomic features of increased costs of direct-acting and oral anticoagulants in a multidisciplinary hospital in 2019–2021","authors":"E. R. Kadyseva, L. Kulagina","doi":"10.33920/med-03-2208-20","DOIUrl":"https://doi.org/10.33920/med-03-2208-20","url":null,"abstract":"The purpose of the work is to analyze the costs of direct-acting anticoagulants and oral anticoagulants from the total cost of medicines by years in a multidisciplinary hospital, as well as to calculate the cost of a daily prophylactic dose of drugs on the example of apixaban and sodium heparin","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122356965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amitriptyline as a reference antidepressant. r ational pharmacotherapy for depression with chronic pain and insomnia 阿米替林作为参考抗抑郁药。抑郁症伴慢性疼痛和失眠的国家药物治疗
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-10
A.D. Akhmedzhanova, M. Maksimov
{"title":"Amitriptyline as a reference antidepressant. r ational pharmacotherapy for depression with chronic pain and insomnia","authors":"A.D. Akhmedzhanova, M. Maksimov","doi":"10.33920/med-03-2208-10","DOIUrl":"https://doi.org/10.33920/med-03-2208-10","url":null,"abstract":"According to WHO, depressive disorders are 4 times more common among patients suffering from chronic pain with insomnia. Insomnia in depression complicated by pain is a clinical syndrome characterized by nocturnal sleep disorders and related disorders during daytime wakefulness, occurring even when there is sufficient time and conditions for sleep. Treatment of insomnia patients with amitriptyline, phenazepam, and bromocamphor reduced the average duration of hospitalization, improved the patients’ quality of life, and reduced the frequency of seeking neurological care.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"110 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124681444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omalizumab adverse reactions and safety Omalizumab的不良反应和安全性
Glavvrač (Chief Medical Officer) Pub Date : 2022-07-25 DOI: 10.33920/med-03-2208-07
K. O. Shnaider, M. Maksimov, B. Romanov, A. Shikaleva
{"title":"Omalizumab adverse reactions and safety","authors":"K. O. Shnaider, M. Maksimov, B. Romanov, A. Shikaleva","doi":"10.33920/med-03-2208-07","DOIUrl":"https://doi.org/10.33920/med-03-2208-07","url":null,"abstract":"Omalizumab is one of the longest-used monoclonal antibodies and the first available treatment option for severe allergic asthma in patients aged 6 years and older. Its efficacy and safety were established in several randomized controlled trials, leading to its final registration over 15 years ago. In most cases, long-term treatment with omalizumab is safe and does not increase the risk of adverse reactions. However, over the years, there has been a trend towards an increase in the registration of adverse events associated with the use of omalizumab.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124317544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信